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Abstract
Background: Hyperglycemia and insulin resistance frequently occur in critically ill and in morbidly obese (MO)
patients. Both conditions are associated with altered serum levels of cytokines and adipokines. In addition, obesity
related alterations in adipokine expression contribute to insulin resistance in metabolic syndrome. In this study we
examined the serum adipocytokine profile in critically ill patients, MO patients, and healthy blood donors.
Methods: 33 patients who fulfilled the clinical criteria for severe sepsis or septic shock (SP) were prospectively
enrolled in this study. A multiplex analysis was performed to evaluate plasma levels of adiponectin, resistin, leptin,
active PAI-1, MCP-1, IL-1 alpha, IL-6, IL-8, IL-10, and TNF-alpha in 33 critically ill patients, 37 MO patients and 60
healthy blood donors (BD).
Results: In SP, adiponectin was significantly lowered and resistin, active PAI-1, MCP-1, IL-1 alpha, IL-6, IL-8, IL-10,
and TNF-alpha were significantly elevated compared to BD. Leptin levels were unchanged. In MO, adiponectin and
IL-8 were significantly lowered, leptin, active PAI-1, MCP-1, IL-1 alpha, IL-6, and IL-10 significantly elevated, whereas
resistin was unaltered.
In SP, adiponectin correlated negatively with BMI, SAPS II and SOFA scores, while resistin correlated positively with
SAPS II and SOFA scores and leptin correlated positively with the BMI. Adiponectin was approximately equally
diminished in SP and MO compared to BD. With the exception of active PAI-1, cytokine levels in SP were clearly
higher compared to MO.
Conclusion: A comparable adipocytokine profile was determined in critically ill and MO patients. As in MO, SP
showed reduced adiponectin levels and elevated MCP-1, active PAI-1, IL-1 alpha, IL-6, and IL-10 levels. Leptin is
only elevated in MO, while resistin, IL-8, and TNF-alpha is only elevated in SP. As in MO patients, increased levels of
proinflammatory cytokines and altered levels of adipokines may contribute to the development of insulin
resistance in critically ill patients.
Background
Sepsis is defined as a systemic inflammatory response
syndrome to infection, which, when associated with one
or more organ system dysfunctions, is considered as
severe sepsis. When sepsis is associated with shock,
which is refractory to fluid resuscitation, the patient is
considered to be in septic shock [1]. This is associated
with an increased production of both pro- and anti-
inflammatory cytokines [2]. Cytokines are low-molecu-
lar-weight polypeptides or glycoproteins that play an
important role in regulating host response to infection,
immune responses, inflammation, and trauma.
Some cytokines clearly promote inflammation and are
called proinflammatory cytokines, whereas other cyto-
kines suppress the activity of proinflammatory cytokines
and are called anti-inflammatory cytokines.
Tumor necrosis factor (TNF) and interleukin (IL)-1a
are proinflammatory cytokines, which can cause fever,
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shock and death [3]. IL-10, a potent anti-inflammatory
cytokine [4], is a key regulator of the immune system and
is essential for homeostasis of the immune system [5].
IL-6, secreted by T cells and macrophages to stimulate
immune response, is an interleukin that can exhibit both,
pro-inflammatory and anti-inflammatory functions.
Another class of proinflammatory peptides are chemo-
kines that selectively recruit monocytes, neutrophils, and
lymphocytes and facilitate the passage from the circula-
tion into the tissues. The prototypical chemokine is the
neutrophil chemoattractant IL-8 [6]. Monocyte che-
moattractant protein-1 (MCP-1) is another key chemo-
kine that regulates migration and infiltration of
monocytes and macrophages [7].
Many of the above mentioned cytokines such as IL-6
or IL-8 are not only synthesized by blood cells, but also
by adipose tissue [8]. Particularly IL-6 could provide a
potential link between fatty tissue and systemic inflam-
mation [9].
In contrast with classical views, adipose tissue not only
provides a depot for fat storage but has been increas-
ingly recognized as an important endocrine organ, man-
ufacturing adipokines, bioactive molecules including
adiponectin, leptin, and resistin, and proinflammatory
cytokines [10]. Below, the adipose tissue derived hor-
mones adiponectin, leptin, and resistin are termed
adipokines.
Whereas adiponectin and resistin are involved in glu-
cose metabolism and exhibit anti-inflammatory features,
leptin plays an important role in feeding behavior and
exhibits proinflammatory features [11]. Plasminogen
activator inhibitor-1 (PAI-1), secreted by adipose tissue
h a sb e e ns h o w nt ob ea ni m p o r t a n ti n h i b i t o ro f
fibrinolysis.
The expressions of these adipokines and cytokines are
changed in obese persons, since obesity is associated
with the appearance of a chronic, low inflammatory
state due to changes in adipocyte and macrophage func-
tion [12]. Obesity leads to lowered levels of the anti-
inflammatory adipokine adiponectin in circulation [13].
Adiponectin is known to be a regulator of insulin sensi-
tivity and glucose metabolism. Furthermore, hypoadipo-
nectinemia has been shown to be associated with insulin
resistance and hyperinsulinemia [14]. Insulin resistance
is one key feature of “metabolic syndrome”,c h a r a c t e r -
ized by a distinct combination of metabolic disorders
such as elevated triglycerides, reduced high densitiy lipo-
proteins, and/or enhanced fasting plasma glucose levels
[15]. As obesity and metabolic syndrome, severe sepsis
and septic shock are linked to increased blood glucose
levels and insulin resistance even without a previous his-
tory of diabetes [16].
Several studies have provided evidence that increased
blood glucose levels impair morbidity and mortality in
critically ill patients and that intensive insulin therapy
aimed at maintaining euglycemia markedly improved
the outcome of these patients [17].
The aetiology of the “insulin resistance syndrome”
caused by sepsis or metabolic syndrome is multifactorial,
and the mechanisms underlying the intercorrelations
among these metabolic conditions are not entirely clear.
Although the involvement of adipose tissue hormones in
the obesity-induced insulin resistance has been studied,
there is only few information about its changes in criti-
cally ill patients [18].
Therefore, the present study was performed to deter-
mine a serum adipocytokine profile in critically ill
patients which was subsequently compared with the
profile of morbidly obese patients and a healthy control
group. Further, we investigated if concentrations of adi-
pocytokines are shifted in the same direction in critically
ill septic patients as in morbidly obese patients com-
pared to healthy controls. If so, which group has higher
resultant changes? These results might increase our
knowledge whether underlying mechanisms for insulin
resistance are comparable in both groups of patients.
Methods
Patients and controls
Septic patients
33 patients in intensive care who fulfilled the clinical
criteria for severe sepsis or septic shock were prospec-
tively enrolled in this study. The criteria for severe sep-
sis and septic shock were in accordance with those
defined by Bone [19]. The Simplified Acute Physiology
Score (SAPS II) and Sequential Organ Failure Assess-
ment score (SOFA) without Glasgow coma scale (GCS)
were used to define the severity of disease and organ
dysfunctions, respectively [20-22]. The underlying causes
of sepsis were intestinal perforation (e.g. perforated
ulcer, perforated diverticular disease; n = 11), inflamma-
tion (e.g. necrotizing pancreatitis, necrotizing fasciitis;
n = 11), postoperative complication (e.g. infections, fis-
tula, anastomosis-insufficiency, n = 7), ischemia (n = 2),
and trauma (n = 2). The 33 septic patients (SP) had
median (range) SAPS II and SOFA scores of 40 (17-60)
and 9 (3-14), respectively. Seven patients had pre-exist-
ing type II diabetes.
Blood samples were collected one day after diagnosis
of severe sepsis or septic shock at 5 a.m. in the fasting
state (10 ml venous blood, collected in a chilled syringe
with EDTA).
Serum was obtained by centrifugation (1800×g for
15 min), and the samples were subsequently stored in
aliquots at -80°C until further analysis.
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index (BMI) of septic patients was self reported (or esti-
mated if no self-report was possible).
Morbidly obese patients and controls
37 consecutive patients operated for morbid obesity
(MO) at the author’s hospital and 60 healthy blood
donors (BD) were enrolled as the group of morbidly
obese patients and as the control group, respectively.
Blood samples from patients diagnosed with MO were
collected preoperatively at 7 a.m. in fasting state. Sam-
ples of BD were taken at various times in no fasting
state (10 ml venous blood, collected in a chilled syringe
with EDTA). Anthropometric data (age and BMI) of
patients of all three groups are listed in table 1.
The study was performed with the permission of the
independent local ethics committee of the University of
Ulm (approvals 112/2003 and 73/2009). An informed
consent of all patients was necessary. If the patient was
not capable of making decisions because of sedation or
altered mental state, the informed consent was obtained
after recovery. Exclusion criteria were: age < 18 years,
pregnancy, rapidly progressing underlying disease, HIV/
AIDS, cardiogenic shock as the primary underlying dis-
ease, underlying hematologic disease, or cytotoxic ther-
apy given within the previous 6 months.
Cytokine and adipocytes-derived hormones measurement
and reagents
Multiplex analysis kits for IL-1a,I L - 6 ,I L - 8 ,I L - 1 0 ,
TNFa, MCP-1, active PAI-1, leptin, resistin, adiponectin
were obtained from Millipore, Hamburg, Germany. In
brief, the appropriate cytokine standards and samples,
diluted in plasma dilution buffer, were added to wells of
a filtered plate. The samples were incubated with 50 μl
of the antibody -coupled microsphere set on a plate sha-
ker in the dark at room temperature for 30 min. The
samples were washed three times with 100 μl wash puf-
fer. Freshly diluted secondary detection antibody (25 μl/
well) was added to the wells and then incubated on a
plate shaker in the dark at room temperature. There-
after, samples were washed three times with 100 μl
wash buffer. Fifty microliters of strepavidin-PE (16 μg/
ml in assay buffer) was added to each well, and incuba-
tion continued on a plate shaker at room temperature
for the first 10 min. Unbound analytes were filtered
through the wells using the vacuum manifold. The
bound beads were washed three times with 100 μlw a s h
buffer. After the last wash step, 125 μl of assay buffer
was added to each well and the plate was placed on a
plate shaker set at 500 rpm for 1 min and then for
3 min at a reduced speed of 300 rpm. Finally, samples
were analyzed on the Luminex system in accordance
with the manufactures’ instruction. As far as reaching
the lowest traceable values, the sensitivity of the method
was 0.3 ng/ml for leptin and 9.2 pg/ml for IL-1a.
Statistical analysis
All values were expressed as median with range.
When comparing data between the three groups, i. e.,
SP, MO and BD, statistical analysis was performed using
the Mann-Whitney U test. Analysis was performed with
WinSTAT, Version 2009.1 (R. FitchSoftware).
The Spearman rank-order correlation coefficient was
calculated for correlation analysis. R indicates the corre-
lation coefficient. A value of p < 0.05 was considered
statistically significant. Correlation coefficient values
between 0.3 and 0.7 (-0.3 and -0.7) indicate a moderate,
values between 0.7 and 1.0 (-0.7 and -1.0) indicate a
strong positive (negative) linear relationship. No adjust-
ment for multiple testing was done.
Results
Adipocytokine levels are clearly changed in septic and
obese patients. For a better overview, serum concentra-
tions of adiponectin, leptin, resistin, TNF-a,M C P - 1 ,
active PAI-1, IL-1a,I L - 6 ,I L - 8 ,I L - 1 0a r es h o w ni n
table 2 and figs. 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.
Table 1 Gender specific anthropometric data (age and BMI) of patients with severe sepsis or septic shock (SP),
morbidly obesity (MO), and healthy control group (BD)
Age [years] (median; range) BMI [kg/m
2] (median; range)
SP (n = 33) 66 years (30 - 87) 26 kg/m
2 (18 - 37)
Female patients (n = 12) 81 years (42 - 87) 26 kg/m
2 (20 - 32)
Male patients (n = 21) 65 years (31 - 85) 26 kg/m
2 (18 - 37)
MO (n = 37) 45 years (17 - 59) 52 kg/m
2 (33 - 78)
Female patients (n = 24) 46 years (23 - 59) 52 kg/m
2 (35 - 78)
Male patients (n = 13) 42 years (17 - 59) 49 kg/m
2 (33 - 70)
Control group (n = 60) 45 years (19 - 71) Not ascertained
Female control (n = 30) 44 years (19 - 60) Not ascertained
Male control (n = 30) 46 years (19 - 71) Not ascertained
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In SP, adiponectin was lowered and resistin elevated
compared to BD. Further, adiponectin correlated nega-
tively with the SAPS II (r = -0.30; p = 0.043) and SOFA
scores (r = -0.31; p = 0.042), while resistin correlated
positively (SAPS II: r = 0.35; p = 0.023; SOFA: r = 0.30;
p = 0.045). Leptin levels were unchanged in SP com-
pared to BD. BMI correlated negatively with adiponectin
(r = 0.32; p = 0.036) and positively with the leptin levels
(r = 0.64; p = < 0.001) in SP. In MO, gender specific
adiponectin was lowered and leptin elevated compared
to BD. Resistin was unaltered. Adiponectin was equally
diminished in SP and MO compared to BD.
As in BD and MO, there was a profound gender dif-
ference in adiponectin levels between male and female
SP (male median levels: 9.3 μg/ml vs. female median
levels: 13.2 μg/ml; p = 0.017).
Cytokines (TNFa, MCP-1, active PAI-1 and interleukins)
All determined cytokines had significantly higher values
in SP compared to BD. In MO, IL-8 was the only
assessed value that showed a significant fall compared to
BD, all other cytokines in MO were significantly ele-
vated. With the exception of active PAI-1, cytokine
levels in SP were clearly higher compared to MO.
Again, in SP there were positive correlations of active
PAI-1, IL-6, IL-8, MCP-1, and IL-10 with SAPS II and
SOFA scores. IL-1a and TNF-a showed no correlation
with SAPS II and SOFA scores. P-values and correlation
coefficients with SAPS II and SOFA scores are: active
PAI-1 (p = 0.032, r = 0.33; p = 0.021. r = 0.34), IL-6
(p = 0.006, r = 0.45; p = 0.030, r = 0.39), IL-8 (p =
0.032, r = 0.31; p = 0.012, r = 0.41), MCP-1 (p = 0.082,
r= 0.29; p = 0.043, r = 0.33), IL-10 (p = 0.040, r = 0.28;
p = 0.074, r = 0.26), IL-1a (p = 0.118, r = -0.21;
p = 0.389, r = -0.05) and TNF-a (p = 0.252, r = 0.13;
p = 0.419, r = 0.04).
Age dependency of values
Since SP were significantly older compared to MO and
BD patients, it is necessary to consider an age depen-
dency of values.
In BD, female adiponectin showed certain correlation
with age (r = 0.34; p = 0.032; male patients: r = -0.26;
Table 2 Gender specific adiponectin and leptin levels and resistin, MCP-1, active PAI-1, TNF-a, IL-1a, IL-6, IL-8, and
IL-10 levels of septic patients (SP), morbidly obese (MO) and controls (BD)
Parameters
(normal values)
SP (n = 33)
(Median; range)
MO (n = 37)
(Median; range)
BD (n = 60)
(Median; range)
Change
SP vs. BD
Change
MO vs. BD
Adiponectin
(μg/ml)
10.3
(2.9 - 47.6)
9.4
(3.8 - 57.8)
14.7
(5.7 - 54.0)
↓
p = < 0.01
↓
p = < 0.01
Adiponectin male (μg/ml) 9.5
(2.9 - 32.6)
8.3
(3.8 - 12.3)
11.8
(5.7 - 30.7)
↓
p = 0.04
↓
p = < 0.01
Adiponectin female (μg/ml) 13.2
(5.3 - 47.6)
12.4
(5.3 - 57.8)
22.5
(9.8 - 54.0)
↓
p = 0.02
↓
p = < 0.01
Leptin (ng/ml) 6.3
(0.3 - 80.7)
45.0
(1.7 - 97.5)
10.8
(0.3 - 58.5)
no significant change ↑
p = < 0.01
Leptin male (ng/ml)
(< 7 ng/ml)
6.3
(0.3 - 24.7)
34.2
(1.7 - 90.9)
4.6
(0.3 - 19.1)
no significant change ↑
p = < 0.01
Leptin female (ng/ml)
(< 18 ng/ml)
8.2
(0.9 - 80.7)
47.3
(16.1 - 97.5)
15.8
(0.7 - 58.5)
no significant change ↑
p = < 0.01
Resistin (ng/ml) 78.1
(13.4 - 52.3)
9.9
(3.7 - 83.6)
10.8
(5.2 - 24.9)
↑
p = < 0.01
no significant change
MCP-1 (pg/ml) 381.5
(72.3 - 887.3)
108
(39.6 - 293)
43.9
(12.1 - 150)
↑
p = < 0.01
↑
p = < 0.01
Active PAI-1 (ng/ml) 35.9
(11.5 - 160.3)
57.5
(3.7 - 176.7)
6.0
(2.4 - 31.3)
↑
p = < 0.01
↑
p = < 0.01
TNF-a (pg/ml) 13.1
(2.4 - 65.5)
4.0
(2.4 - 26.8)
3.9
(1.2 - 10.9)
↑
p = < 0.01
no significant change
IL-1a (pg/ml) 68.6
(9.2 - 203.3)
59.4
(9.2 - 210.0)
11.0
(9.2 - 168)
↑
p = 0.04
↑
p = 0.01
IL-6 (pg/ml) 163.6
(14.4 - 10000)
2.9
(0.9 - 64.2)
0.7
(0.4 - 568.6)
↑
p = < 0.01
↑
p = < 0.01
IL-8 (pg/ml) 59.4
(4.6 - 1335.6)
3.7
(0.3 - 38.8)
9.8
(0.9 - 126.7)
↑
p = < 0.01
↓
p = < 0.01
IL-10 (pg/ml) 26.7
(3.9 - 276.7)
2.5
(2.4 - 8.6)
1.2
(0.9 - 1038)
↑
p = < 0.01
↑
p = 0.01
↓↑: Significant increase/decrease;
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Page 4 of 9p = 0.085). There was no correlation with patients’ age
in BD concerning female/male leptin, resistin, active
PAI-1, MCP-1, IL-1a, IL-6, IL-8; IL-10, and TNF-a.
Values of MO and SP showed no correlation with age.
Seven patients of the sepsis group had preexisting type
2 diabetes. These seven patients showed no difference in
adiponectin, resistin, leptin, active PAI-1, MCP-1, IL-1a,
IL-6, IL-8, IL-10, and TNF-alpha levels.
Discussion
In this study we determined serum levels of classical
cytokines and adipokines in septic and morbidly obese
patients and compared them to healthy blood donors.
T h em o s ti m p o r t a n tf i n d i n go ft h i ss t u d yi st h a tb o t h ,
SP and MO have similarly shifted values compared to a
control group of healthy BD. Moreover, most cytokine
concentrations were greater in sepsis patients than in
the morbidly obese patients.
Adipokines
Our results revealed that the only known adipose tissue
derived factor with major insulin-sensitizing and anti-
inflammatory properties, adiponectin, is equally dimin-
ished in SP and MO. Adiponectin is the most abundant
protein produced by adipose tissue and its blood con-
centration is much higher than the concentration of
other known hormones. Normal serum adiponectin
levels are higher in women compared to men. Adipo-
nectin attenuates inflammatory actions on several levels.
It suppresses function of mature macrophages and inhi-
bits growth of macrophage precursors [23]. Further,
adiponectin attenuates the production of TNF-a and
IL-6 production in macrophages and induces that of
IL-10 [24]. Thus, the lower levels of adiponectin in the
Figure 1 Gender specific serum concentrations of adiponectin
in septic (SP) and morbidly obese (MO) patients and healthy
controls (BD). The top and bottom of the rectangle represent the
25th and 75th percentile. The line within the rectangle represents
the median. The whiskers extend from the 5th percentile to the
95th percentile.
Figure 2 Gender specific serum concentrations of leptin in
septic (SP) and morbidly obese (MO) patients and healthy
controls (BD).
Figure 3 Serum concentrations of resistin in septic (SP) and
morbidly obese (MO) patients and healthy controls (BD).
Figure 4 Serum concentrations of MCP-1 in septic (SP) and
morbidly obese (MO) patients and healthy controls (BD).
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comparison to healthy controls might have contributed
to the higher levels of IL-6 and TNF-a. Otherwise, adi-
ponectin has an insulin sensitizing effect. Adiponectin
levels decrease in parallel with the progression of insulin
resistance and type 2 diabetes [25], and the antidiabetic
drug thiazolidinedione increases adiponectin levels [26].
Given the anti-inflammatory effects of adiponectin, it is
plausible that lowered adiponectin levels may predispose
to sepsis-related proinflammatory complications in
states of obesity, diabetes, and insulin resistance. On the
other hand, the reduced adiponectin levels in our sepsis
patients might support insulin resistance. Several other
studies also showed lower adiponektin levels in septic
patients [27,28].
Besides adiponectin, resistin has been reported to
participate in the inflammatory response [29]. Resistin
was originally discovered in mice as an adipocytes
d e r i v e dh o r m o n e .I tw a sf o u n dt ob ei n c r e a s e di n
obesity and causing insulin resistance in mice [30]. In
contrast to mice, resistin in humans is mainly derived
from macrophages rather than adipocytes [31]. In
humans, resistin is a protein with proinflammatory
properties. Its secretion is stimulated by inflammatory
processes, glucocorticoids and lipopolysaccharides
(LPS), whereas TNF-a and b-adrenergic stimulation
a c ta si n h i b i t o r s[ 3 2 ] .R e s i s t i nh a sb e e ns h o w nt o
increase transcriptional events leading to an increased
expression of several pro-inflammatory cytokines
including IL-1, IL-6, IL-12, and TNF-a [33]. In a posi-
tive feedback loop, resistin can be up-regulated by
interleukins, and also by microbial antigens such as
LPS [34]. In accordance with these reports, we found
significantly higher resistin levels in SP, but not in
MO, compared to healthy BD supporting the hypoth-
esis that in humans resistin is predominantly a compo-
nent of the systemic inflammatory response to
infection.
Figure 5 Serum concentrations of active PAI-1 in septic (SP)
and morbidly obese (MO) patients and healthy controls (BD).
Figure 6 Serum concentrations of TNF-a in septic (SP) and
morbidly obese (MO) patients and healthy controls (BD).
Figure 8 Serum concentrations of IL-6 in septic (SP) and
morbidly obese (MO) patients and healthy controls (BD).
Figure 7 Serum concentrations of IL-1a in septic (SP) and
morbidly obese (MO) patients and healthy controls (BD).
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than in MO, this could have led to the higher resistin
levels in SP than in MO in our study. Otherwise, the
higher resistin levels in SP compared to MO may have
contributed to the higher pro-inflammatory cytokines in
SP compared to MO. In our SP and MO patients, as
well as in prior studies of septic patients [35,36], resistin
did not correlate to obesity measured by BMI which
suggests that in circumstances of critical illness the
release of resistin by macrophages plays a superior role
compared with the secretion from adipocytes. This
could possibly also explain why there was no difference
in resistin levels of patients with preexisting diabetes
mellitus.
Leptin was the only measured adipokine in the present
study that was marginally reduced in SP compared to
BD. The MO group had significantly elevated levels. In
the present study, normal leptin serum levels were
higher in women compared to men. In the obese,
increased fat storage will lead to enhanced leptin levels
[37]. Leptin can affect glucose metabolism and increases
insulin sensitivity. Obese humans are often insulin- and
leptin-resistant [38]. The role of leptin in sepsis and sep-
tic shock is controversial. Earlier reports suggested that
high lepin levels are associated with increased survival
in sepsis and septic shock [39,40], several other reports
-such as our study- fail to show a correlation between
leptin and sepsis [41]. Our minor changes of leptin
serum levels in SP are in line with a reported temporal
decrease in leptin after operative stress followed by a
subsequent rise slightly above the initial levels [42].
Cytokines
Several studies suggest that TNF-a and IL-6 are both
involved in obesity-related insulin resistance and that
TNF-a is one of the most important mediators of
inflammation [43]. TNF-a is not secreted by adipocytes
but by infiltrating macrophages in adipose tissue,
whereas adipose tissue is a significant source of IL-6
[44]. Expression and secretion of TNF-a increases with
obesity and correlates positively with body mass index
[45]. TNF-a and IL-6 are known to promote lipolysis
and the secretion of free fatty acids, which contributes
to an increase in hepatic glucose production and insulin
resistance [46]. On a cellular level, TNF-a is a potent
inhibitor of the insulin-stimulated tyrosine phosphoryla-
tions on the beta-chain of the insulin receptor and insu-
lin receptor substrate-1, suggesting that TNF-a may
play a crucial role in the systemic insulin resistance of
non insulin dependent diabetes mellitus [47]. In analogy,
the elevated IL-6 levels in our septic and morbidly obese
patients may contribute to insulin resistance. In contrast
to the morbidly obese patients, in addition, the elevated
TNF-a levels in our septic patients might play a role in
insulin resistance.
Human fat cells are also known to produce proinflam-
matory IL-8 which was increased in insulin-resistant
subjects [48]. Surprisingly, we found reduced levels of
IL-8 in MO compared to BD. Serum levels of MO
patients (median: 3.7 pg/ml) match reported levels in
the obese. Serum level of BD seems (median: 9.8 pg/ml)
markedly elevated compared to reported levels of
approximately 3.2 pg/ml [49]. Insofar, reported IL-8
levels should be interpreted with care. Nevertheless, the
higher IL-8 levels in septic patients compared to the
morbidly obese patients underline the infection induced
origin of IL-8 in our study.
The presented study has several limitations. In the
healthy control group, there was no investigation of hid-
den or not yet clinically manifest side diagnoses. Conse-
quently, there is no information about type 2 diabetes
or other chronic inflammatory diseases without clinical
manifestation. Moreover, the control group was
Figure 9 Serum concentrations of IL-8 in septic (SP) and
morbidly obese (MO) patients and healthy controls (BD).
Figure 10 Serum concentrations of IL-10 in septic (SP) and
morbidly obese (MO) patients and healthy controls (BD).
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samples were not taken in fasting state in the control
group. However, only leptin showed a significant corre-
lation with the blood donor’s age in the control group,
whereas resistin, IL-1a, IL-6, and IL-8 did not. Thus,
the differences between these values in the septic
patients group and control group may be less striking.
Further, no weight/height for BMI calculation was ascer-
tained in BD group. Another crucial points are the small
number and the heterogeneousness of the septic group
including patients with different cause of sepsis. How-
ever, this reflects the typical clinical situation and case
mix in intensive care units.
It is also important to note that many other factors in
addition to proinflammatory cytokines such as cortisol,
catecholamines, growth hormone, and other stress-
related factors can significantly contribute to the devel-
opment of insulin resistance in critically ill patients [50].
Conclusion
In conclusion, we could determine a sepsis specific adi-
pocytokine profile in critically ill patients. In comparison
with levels in a healthy control group, we observed a
marked reduction of adiponectin and a profound
increase of resistin, active PAI-1, MCP-1, IL-1a,I L - 6 ,
IL-8, IL-10, and TNF-a in septic patients. As in SP, MO
showed reduced adiponectin levels and elevated MCP-1,
active PAI-1, IL-1a, IL-6, and IL-10 levels. Leptin is
only elevated in MO, while resistin, IL-8, and TNF-a is
only elevated in SP. Taken together, the finding of
increased levels of proinflammatory cytokines and
altered levels of adipokines underlines its possible con-
tribution in the development of insulin resistance in cri-
tically ill patients with sepsis.
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